Back

All stented patients with atrial fibrillation, stable one year after intervention, should be managed with oral anticoagulants, without antiplatelets - CONTRA.

3 March 2018 (15:00 - 15:15)
Organised by:
Congress Presentation Part of: Controversies on anticoagulants post-MI antithrombotic treatment Acute Coronary Syndromes: Post-Infarction Period ACVC Premium Access Acute Cardiovascular Care 2018

About the speaker

Photo
Professor Christopher B Granger

Duke University Medical Center, Durham (United States of America)

9 More presentations in this session

Presentation thumbnail
Low dose of rivaroxaban is a significant achievement for post-MI patients with atherosclerosis. Antiplatelets alone are not enough - PRO.
Doctor A. Rubboli (Ravenna, IT)
Slides Video
Presentation thumbnail
Low dose of rivaroxaban is a significant achievement for post-MI patients with atherosclerosis. Antiplatelets alone are not enough - CONTRA.
Professor R. Storey (Sheffield, GB)
Slides Video
Presentation thumbnail
Low dose of rivaroxaban is a significant achievement for post-MI patients with atherosclerosis. Antiplatelets alone are not enough - Rebuttal PRO.
Doctor A. Rubboli (Ravenna, IT)
Presentation thumbnail
Low dose of rivaroxaban is a significant achievement for post-MI patients with atherosclerosis. Antiplatelets alone are not enough - Rebuttal CONTRA.
Professor R. Storey (Sheffield, GB)
Presentation thumbnail
Low dose of rivaroxaban is a significant achievement for post-MI patients with atherosclerosis. Antiplatelets alone are not enough: Chairpersons conclusion

Access the full session

Session thumbnail
Controversies on anticoagulants post-MI antithrombotic treatment

The Event

Event poster

Acute Cardiovascular Care 2018

3 March 2018 15:00 CET
You may be interested in
thumbnail
Congress Presentation
Reduction of major adverse and major cardiovascular events in patients with atrial fibrillation and stent implantation treated with left atrial occlusion device vs oral anticoagulants strategy.
26 August 2022
thumbnail
Congress Presentation
Effect of anti-coagulation in elderly patients with atrial fibrillation
23 April 2021
thumbnail
Congress Presentation
Association between personalized evidence-based anticoagulation therapy and outcomes at 1-year follow-up in patients with atrial fibrillation: an analysis from the Atrial Fibrillation Registry
29 June 2021
thumbnail
Congress Presentation
Cardiac resynchronization therapy in permanent atrial fibrillation
22 May 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources